open access

Vol 64, No 3 (2013)
Original papers
Published online: 2013-07-01
Submitted: 2013-07-31
Get Citation

Safety and efficiency of treatment with cinacalcet of haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism

Piotr Kuczera, Marcin Adamczak, Andrzej Więcek
Endokrynologia Polska 2013;64(3):176-181.

open access

Vol 64, No 3 (2013)
Original papers
Published online: 2013-07-01
Submitted: 2013-07-31

Abstract


Introduction: Secondary hyperparathyroidism (sHPT) is a common disorder in haemodialysed patients with chronic kidney disease (CKD). Cinacalcet increases the sensitivity of calcium receptor to the serum calcium, thus reducing serum parathormone (PTH) concentration. The aim of this study was to assess the safety and efficacy of six-month treatment with cinacalcet in haemodialysed CKD patients with sHPT in upper Silesia.
Material and methods: 300 pg/mL) were enrolled in this study. The target was to decrease PTH concentration below 300 pg/mL. PTH (ECL; Roche, Mannheim, Germany), calcium and phosphate concentration was assessed before the first dose of cinacalcet and then after three and six months of treatment, before haemodialysis session. The results are shown as means and 95% confidence index.
Results: 58 patients completed the study. There was a significant decrease in serum PTH concentration from 1,138 pg/mL (931&#8211;1,345 pg/mL) to 772 pg/mL (551&#8211;992 pg/mL) after three months of treatment (p < 0.0001) and to 635 pg/mL (430-839 pg/mL; p < 0.0001) after six months. The target PTH concentration was reached in 25% of the patients after three months and in 45% after six months of treatment. Cinacalcet was ineffective in decreasing serum PTH in 16 (28%) patients. There were no significant differences in serum calcium and phosphate concentration during the observation period.
Conclusions:
1. Cinacalcet decreases serum PTH concentration in most haemodialysed CKD patients with sHPT.
2. In 28% of patients, resistance to treatment with cinacalcet was observed.
3. Cinacalcet treatment was well tolerated and caused only a few side effects. (Endokrynol Pol 2013; 64 (2): 176&#8211;181)

Abstract


Introduction: Secondary hyperparathyroidism (sHPT) is a common disorder in haemodialysed patients with chronic kidney disease (CKD). Cinacalcet increases the sensitivity of calcium receptor to the serum calcium, thus reducing serum parathormone (PTH) concentration. The aim of this study was to assess the safety and efficacy of six-month treatment with cinacalcet in haemodialysed CKD patients with sHPT in upper Silesia.
Material and methods: 300 pg/mL) were enrolled in this study. The target was to decrease PTH concentration below 300 pg/mL. PTH (ECL; Roche, Mannheim, Germany), calcium and phosphate concentration was assessed before the first dose of cinacalcet and then after three and six months of treatment, before haemodialysis session. The results are shown as means and 95% confidence index.
Results: 58 patients completed the study. There was a significant decrease in serum PTH concentration from 1,138 pg/mL (931&#8211;1,345 pg/mL) to 772 pg/mL (551&#8211;992 pg/mL) after three months of treatment (p < 0.0001) and to 635 pg/mL (430-839 pg/mL; p < 0.0001) after six months. The target PTH concentration was reached in 25% of the patients after three months and in 45% after six months of treatment. Cinacalcet was ineffective in decreasing serum PTH in 16 (28%) patients. There were no significant differences in serum calcium and phosphate concentration during the observation period.
Conclusions:
1. Cinacalcet decreases serum PTH concentration in most haemodialysed CKD patients with sHPT.
2. In 28% of patients, resistance to treatment with cinacalcet was observed.
3. Cinacalcet treatment was well tolerated and caused only a few side effects. (Endokrynol Pol 2013; 64 (2): 176&#8211;181)
Get Citation

Keywords

cinacalcet; end stage kidney disease; haemodialysis; secondary hyperparathyroidism

About this article
Title

Safety and efficiency of treatment with cinacalcet of haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism

Journal

Endokrynologia Polska

Issue

Vol 64, No 3 (2013)

Pages

176-181

Published online

2013-07-01

Bibliographic record

Endokrynologia Polska 2013;64(3):176-181.

Keywords

cinacalcet
end stage kidney disease
haemodialysis
secondary hyperparathyroidism

Authors

Piotr Kuczera
Marcin Adamczak
Andrzej Więcek

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl